Pyrazole heterocycle is regarded as an extremely significant agent for the therapy of inflammation. Celecoxib, lonazolac, deracoxib, and phenylbutazone are examples of commercially approved pyrazole drugs with COX-2 inhibitory potential for curing inflammation. There have been recently many reviews for the biological significance of pyrazole derivatives. This review talks about pyrazole derivatives with anti-inflammatory activity and also sheds the light on the recent updates on pyrazole research with an emphasis on some synthetic pathways utilized to construct this privileged scaffold and structure activity relationship that accounts for the anti-inflammatory activity in an attempt to pave the opportunity for medicinal chemists to develop novel anti-inflammatory agents with better COX-2 selectivity.

01 Mar 2025·Journal of Veterinary Internal Medicine

Effect of Phenylbutazone Administration on Insulin Sensitivity in Horses With Insulin Dysregulation

Article

Author: Skinner, Jazmine E. ; Kemp, Kate L. ; Yuen, Nicholas K. Y. ; Bertin, François‐René

ABSTRACTBackgroundPhenylbutazone is prescribed to manage pain caused by hyperinsulinemia‐associated laminitis. Phenylbutazone reduces glucose and insulin concentrations in horses with insulin dysregulation (ID) but the underlying mechanism of action is unknown.Hypothesis/ObjectivesInvestigate the effect of phenylbutazone on tissue insulin sensitivity in horses. It is hypothesized that the reduced glucose and insulin concentrations in horses with ID receiving phenylbutazone are mediated by a higher tissue insulin sensitivity.AnimalsFifteen light breed horses, including seven with ID.MethodsRandomized cross‐over study. Horses underwent a modified frequently sampled intravenous glucose tolerance test (mFSIGTT) after 8 days of treatment with phenylbutazone (4.4 mg/kg IV daily) or placebo (5 mL 0.9% saline IV daily). After a 10‐day washout period, horses received the alternative treatment for 8 days and a second mFSIGTT. Minimal model analysis was performed, and the effects of ID status and phenylbutazone were investigated with p < 0.05 considered significant.ResultsIn horses with ID, phenylbutazone increased tissue insulin sensitivity index (median [interquartile range]: 0.39 [0.14–0.74] vs. 0.56 [0.55–1.18] ×10−4 L/mIU/min, p = 0.03), and decreased glucose (21 726 [19 040–24 948] vs. 22 909 [22 496–26 166] mg/dL × min, p = 0.02) and insulin (19 595 [16 147—29 698] vs. 22 752 [20 578—31 826] μIU/mL × min, p = 0.03) areas under the curves. No effect was detected in horses administered placebo.Conclusion and Clinical ImportancePhenylbutazone reduces insulin concentration in horses with ID by modulating tissue insulin sensitivity, suggesting that its relevance in the management of ID can extend beyond laminitis‐associated pain.

01 Mar 2025·Journal of Molecular Structure

Construction of a wavelength tunable supramolecular fluorescent probe for serum albumin-mediated live cell imaging

Author: Xu, Shao-Hu ; Chang, Kai-Li ; Qin, Wen-Xuan ; Wang, Qing ; Zhang, Jing

A wavelength-tunable supramol. fluorescent probe for live cell imaging mediated by serum albumin was successfully crafted, leveraging the assembly of host-guest complexes formed between water-soluble pillar[5]arene (WP5) and the N-heteroaromatic fluorescent probes DMM and DDM, resp.Both the complexes demonstrated selective responsiveness towards bovine serum albumin (BSA), accompanied by favorable BSA binding abilities and remarkable anti-interference properties in their BSA responsiveness.Notably, the WP5⊃DMM and WP5⊃DDM complexes shared these exceptional attributes, which were inherent to DMM and DDM, resp.Importantly, the formation of complexes with WP5 did not adversely impact their responsiveness or binding abilities to BSA.In response to BSA, the WP5⊃DMM and WP5⊃DDM complexes exhibited relatively fixed but distinct excitation and emission bands.Apart from this characteristic, these complexes displayed no significant differences in other properties, even when self-assembled into spherical supramol. fluorescent probes in aqueous solutionThus, it became feasible to achieve multicolor imaging in live cells mediated by serum albumin by adjusting the ratio of WP5⊃DMM and WP5⊃DDM complexes within the supramol. fluorescent probes.

News (Medical) associated with Phenylbutazone

10 Dec 2024

·www.businesswire.com

Aegis Sciences Corporation Announces Updates for NPS Testing

NASHVILLE, Tenn.--( BUSINESS WIRE )-- Aegis Sciences Corporation , a health care testing lab based in Nashville, TN, is pleased to announce the second bi-annual update to its novel psychoactive substance (NPS) testing menu. Aegis regularly updates its testing menu based on recommendations established collaboratively by the Center for Forensic Science Research and Education (CFSRE) and the Society of Forensic Toxicologist (SOFT) NPS Committee. Updates to the testing menu include CFSRE’s tier one and tier two scope recommendations for Quarter 3 of 2024. “Aegis is committed to staying current by developing definitive analytical methods that can detect new compounds that reflect actual drug use trends in the market,” said Dr. Rebecca Heltsley, Senior Vice President, Research and Development at Aegis Sciences Corporation. Aegis’s NPS testing menu is reviewed regularly to augment the offering in a manner that allows it to maintain clinical relevance. Updates will include o/m/p-Methylfentanyl, a fentanyl analog that has recently been identified as circulating at a greater frequency, N-Isopropyl Butylone, a substituted cathinone that has been detected in illicit drug material with methamphetamine, and phenylbutazone, a nonsteroidal anti-inflammatory drug removed from the pharmaceutical market that is being found as an adulterant in the illicit drug supply. “High-risk substances that are in circulation are ever-changing, and through the use of Aegis’s definitive testing, clinicians are able to refine and improve harm reduction and overdose prevention strategies,” said Dr. Josh Schrecker, Sr. Dir. of Clinical Affairs at Aegis Sciences Corporation. “This update is tangible proof of our commitment that we will continue to provide our clients with the best tools available to achieve a clear understanding of the illicit substance impacting their communities and to manage risk,” said Dr. Frank Basile, CEO of Aegis Sciences Corporation. Health care practitioners can learn more about the updated test offering through the Aegis website: https://www.aegislabs.com/services/novel-psychoactive-substances/ About Aegis Sciences Corporation Founded in 1990, Aegis Sciences Corporation is a laboratory sciences company based in Nashville, Tenn., that provides science-driven testing and consulting services for clients such as health care providers, pharmaceutical companies, professional and amateur sports organizations, leading college and university athletic programs, Fortune 500 corporations, and government agencies throughout the United States. For more information, please visit http://www.aegislabs.com/ .

100 Deals associated with Phenylbutazone

External Link

KEGG	Wiki	ATC	Drug Bank
D00510	Phenylbutazone	M02AA01 M01AA01	DB00812

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis